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Abstract 
FULLERENE C70 DERIVATIVES DAMPEN ALLERGIC AIRWAY INFLAMMATION, 
BRONCHOCONSTRICTION, AND SYSTEMIC ANAPHYLAXIS 
 
By Sarah B. Norton, Ph.D.   
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2012 
Director:  Daniel H. Conrad, Professor, Department of Microbiology and Immunology 
 
Fullerenes are carbon nanospheres that can be solublized by the addition of polar 
chemical groups to the carbon cage, forming fullerene derivatives.  One specifically 
derivatized fullerene compound, termed C70-Tetragylocolate (C70-TGA), has been 
shown to stabilize mast cell responses in vitro thus we hypothesized it may have an 
effect on mast cell-driven diseases such as asthma and systemic anaphylaxis.  To 
observe the effects of C70-TGA on systemic anaphylaxis, mice were subjected to a 
model of passive systemic anaphylaxis.  In this model, mice were injected with DNP-
specific IgE 16 hours prior to challenge, then treated with C70-TGA.  Immediately prior to 
DNP challenge, mice were subjected to a second injection of C70-TGA.  Following DNP 
challenge, body temperature was recorded and blood was collected for quantitation of 
histamine levels.  Treatment with C70-TGA significantly reduced body temperature drop 
associated with systemic anaphylaxis and serum histamine levels.  To observe the 
effects of C70-TGA on chronic features of asthma in vivo, we utilized a heavily MC 
influenced model of asthma pathogenesis.  Mice were sensitized by intraperitoneal (i.p.) 
injection of ovalbumin (OVA) in saline, challenged intranasally (i.n.) with OVA, and one 
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of two treatment strategies was pursued.  In one, C70-TGA was given i.n. throughout 
disease development.  In the other, C70-TGA was given following an initial set of 
challenges to allow disease to develop prior to treatment; mice were then re-challenged 
with OVA to assess the effect on established disease.  We found that C70-TGA 
treatment significantly reduced airway inflammation and eosinophilia and dramatically 
reduced bronchoconstriction in either model.  Cytokines IL-4 and IL-5 and serum IgE 
levels are significantly reduced in C70-TGA treated animals.  Interestingly, we also saw 
an increase in the anti-inflammatory eicosanoid 11, 12-epoxyeicosatreinoic acid (11,12-
EET) in the BAL fluid, suggesting the involvement of this mediator in C70-TGA inhibition.  
Further experiments utilizing an inhibitor of 11,12-EET formation (6-(2-
Propargyloxyphenyl)hexanoic acid) and a structural analog of 14,15-EET (14,15-EE-
5(Z)-E) in vivo indicate that these mediators are closely associated with C70-TGA 
mediated inhibition as their inhibition reverses the anti-inflammatory effects of C70-TGA.  
Importantly, mice did not exhibit any acute toxicity following C70-TGA treatment and liver 
and kidney function were normal.  Collectively, these results show that the fullerene C70 
derivative C70-TGA is capable of dampening severe allergic responses including 
systemic anaphylaxis, airway inflammation, and bronchoconstriction.  The mechanism 
of inhibition is through the upregulation of the anti-inflammatory EETs, which may 
dampen mast cell degranulation in vivo, thus contributing to the inhibitory effect of 
C70-TGA on allergic disease
  
1 
 
Introduction 
I. Nanoparticles 
Nanoparticles include natural and manufactured molecules measuring less than 
100 nanometers that have a variety of uses in manufacturing, household products, and 
more recently, in medicine.  Nanomedicine is a rapidly developing field with new uses 
for nanoparticles emerging in multiple disciplines.  Both nanotubes and fullerenes 
(Figure 1) are subsets of nanoparticles that have been particularly well studied due to 
their diverse applications in medicine. These small molecules are useful in diagnostics 
such as magnetic resonance imaging and x-ray imaging 1-3, and are being investigated 
for use in improving drug delivery and as anti-inflammatories and radiation 
countermeasures1.  Fullerenes, in particular, are exceptional antioxidants and have 
been proposed as therapeutics for the treatment of a wide range of neurodegenerative 
and inflammatory diseases 4-8.  Oxidative stress, created when reactive oxygen species 
(ROS) outnumber antioxidants, contributes substantially to these diseases.  Therefore 
the antioxidant properties of fullerenes combined with the ability to add cell-type 
targeting derivatives to the fullerene core gives these molecules a novel therapeutic 
advantage in the treatment of such diseases 9-13.  Because ROS play a role in both the 
initiation and progression of inflammatory diseases the ability to quench these highly 
reactive molecules could lead to better therapeutic alternatives for neurodegenerative 
and inflammatory diseases that are currently quite difficult to treat. 
 Fullerenes are hollow spheres measuring roughly one nanometer in diameter.  
They are composed entirely of carbon atoms and are extremely stable owing to their 
aromatic structure which incorporates a large number of carbon-carbon double bonds14.  
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Figure 1. Native fullerene C60, containing 60 carbon atoms (a) and C70, containing 70 
carbon atoms (b).  The C60 fullerene is the most common in nature. 
A. B. 
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Due to their naturally electron deficient state fullerenes are easily attacked by oxygen 
free radicals, making them extremely efficient antioxidants 15. This is how they are 
thought to derive their anti-inflammatory and neuroprotective functions, preventing the 
binding of free radicals to lipids, DNA, proteins, and other macromolecules and thus 
reducing cellular damage commonly induced by these highly reactive molecules 16,17. 
 Fullerenes were discovered in 1985, when it was found that vaporization of 
carbon species from the surface of graphite yielded a stable cluster consisting of 60 
carbon atoms when analyzed with a mass spectrometer 18.  Fullerenes consisting of 70, 
80, or more carbon atoms also exist, but are much less frequent in nature.  Initially, 
fullerenes were of interest for their potential use in chemical processes. More recently 
there has been a growing interest in their application in nanomedicine due to their small 
size, stable nature, and natural antioxidant capabilities. 
 In their native state fullerenes are virtually insoluble in water but solubility can be 
increased by the addition of polar chemical groups to the carbon cage 19,20.  Thus far, all 
studies concerning fullerene distribution in the lungs have been performed using native 
fullerenes, which are hydrophobic and insoluble in aqueous solution.  Distribution of 
fullerenes derivatized to increase solubility in aqueous solution has yet to be explored.  
Further, as the specific moieties added to the carbon cage can greatly affect tissue 
distribution, cellular targeting and toxicity, each compound will need to be examined 
separately.  Specific chemical moieties also affect biological function, therefore a 
specific functional analysis will need to be made for each unique compound.  Current 
knowledge of in vivo fullerene trafficking makes it difficult to answer even rudimentary 
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questions, thus further studies will need to be performed before these compounds are 
considered safe for medical purposes. 
 Previous studies with native fullerenes do give us some insight into fullerene 
distribution, accumulation, and elimination.  When fullerenes are inhaled, their 
deposition in the lung is dependent on their size, where smaller molecules are 
deposited lower in the airway.  While fullerene derivatives can vary in size, the majority 
of these compounds are small enough that they should settle in the tracheobronchial 
and alveolar regions.  Here fullerene compounds can access the bloodstream or 
lymphatics, from which they are distributed to internal organs 21.   
Initial research with polyhydroxylated fullerene compounds shows inhibition of 
mast cell responses including degranulation and inflammatory cytokine production.  
These non-specific compounds did not affect IgE binding to the mast cell surface, but 
instead were localized within the cell in vitro and were shown to reduce ROS generation 
in mast cells treated overnight with fullerene compounds 22.  More recent work identifies 
the differential effects of fullerene compounds on mast cells are dependent on the 
specific moieties added to the carbon cage 23. It is important to identify how the specific 
moieties added to the fullerene core affect mast cells and other inflammatory cells in 
addition to characterizing trafficking of these compounds through the body.  This will 
allow the generation of safe and efficient compounds for use in the treatment of human 
disease. 
 Mast cells may not be the only cells affected by fullerenes as several 
inflammatory cell types are activated and reside in the lung throughout the course of 
allergic disease 24.  Once inhaled, fullerenes likely come into immediate contact with 
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epithelial cells lining the airways.  In asthmatic patients airway epithelial cells are 
activated and produce many of the chemokines that contribute to inflammatory cell 
recruitment, including the eotaxins that recruit eosinophils and thymus- and activation-
regulated chemokine (TARC), a potent chemoattractant for Th2 lymphocytes 25,26.  
Fullerenes may also come into contact with Th2 cells or eosinophils that are recruited to 
the airways, inhibiting critical cytokine and chemokine production by these cells, and 
thus reducing airway inflammation. 
 
II. Asthma and Allergic Disease 
Asthma is a chronic inflammatory disease of the lungs characterized by eosinophil 
infiltration into the airways, increased levels of inflammatory cytokines and chemokines 
in the lungs, and airway hyperresponsiveness to otherwise innocuous substances 27-30.   
Bronchial hyperresponsiveness leads to bronchospasm which reduces airflow into the 
lungs, causing the patient to become hypoxic and hypercapnic.  If airflow restriction is 
not relieved metabolic alterations and exhaustion will cause respiratory arrest and 
death.  Each year over four thousand individuals die as a direct result of asthma, and it 
is the one of the leading causes of cardiac arrest in young patients 31,32  Thus, the 
search for promising new therapeutics is ongoing.  Oxidative stress has been shown to 
contribute to asthma and related lung diseases, hence derivatized fullerenes may 
represent an effective alternative to current treatments 33,34.  Further, the biological 
actions of fullerenes have not been fully elucidated as of yet and thus fullerenes may 
prove efficacious against less treatable subsets of asthma, such as steroid resistant 
asthma, filling a major void in the treatment of asthma.  Patients at the greatest risk of 
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cardiac arrest are those who are unable to control disease with current therapeutics, 
thus these individuals stand to gain enormously from the development of novel 
therapeutics with unique mechanisms of action.  Additional research is necessary to 
determine the therapeutic value of derivatized fullerenes in the treatment of asthma and 
other allergic diseases. 
 
III. Allergic Sensitization, Inflammation, and Current treatments 
Allergic sensitization begins the first time an allergen enters the body, where it is 
processed by antigen presenting cells and peptides are presented to allergen specific 
naïve T cells, driving them towards a TH2 phenotype.  Activated TH2 cells produce a 
variety of cytokines which perform a wide range of functions to promote the initiation 
and progression of disease.  Interleukin-4 and IL-13 induce B cell class switching to IgE 
in humans, while in mice IL-4 exclusively performs this function.  Once B cells have 
been activated and stimulated to class switch they will begin producing large quantities 
of IgE.  This immunoglobulin is released into the circulation and eventually binds its high 
affinity receptor FcεRI on the surface of mast cells and basophils, sensitizing them to 
future encounters with this allergen.  Production of IL-9 by TH2 cells, in addition to IL-4 
and IL-13, further mediates recruitment of mast cells to the lung and stimulates their 
proliferation; basophil maturation is induced by IL-3 and IL-4 production.  In addition to 
its role in B cell activation, IL-13 also contributes to goblet cell metaplasia, mucus 
overproduction, and airway remodeling, processes that combine to increase airway 
obstruction and hyperresponsiveness to stimuli 30,35.  
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 If exposure to allergen is infrequent, inflammation will resolve and symptoms will 
subside.  However, when allergen exposure is repetitive, chronic inflammation 
develops.  Immune cells including eosinophils, basophils, T cells, and B cells are 
recruited to the lungs and remain there indefinitely.  Mast cell numbers increase in the 
airways and these cells are increasingly activated, producing cytokines and other 
inflammatory mediators such as histamine and leukotrienes that maintain inflammation 
in the lung tissue.  Airway inflammation persists chronically and symptoms of disease 
including bronchoconstriction are exacerbated36. 
 Eosinophil infiltration of the airways is one of the defining characteristics of 
asthmatic disease.  The recruitment and stimulation of eosinophils is mediated by IL-5, 
initially produced by TH2 cells.  Once activated, eosinophils themselves produce IL-5 
and other inflammatory cytokines including IL-4 and IL-13, which induce B cell class 
switching and  thus feed back to exacerbate the inflammatory process 37,38.  While the 
specific role of eosinophils in asthma pathogenesis is largely unknown, they are 
considered to be important mediators of disease through their production of 
inflammatory cytokines and their role in airway remodeling 39,40.  The extent of 
eosinophil infiltration into the airways has been shown to correlate with disease 
severity41. 
Neutralization of the major cytokines involved in asthma has been attempted 
therapeutically but has met with little success.  Treatment with a soluble human IL-4 
receptor appeared efficacious in Phase II trials involving patients with mild to moderate 
asthma 42,43, but Phase III trials failed to confirm efficacy.  Antibodies targeting IL-13 or 
the IL-13 receptor show promise but are still in clinical trials 44.  The therapeutic use of 
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anti-IL-5 antibodies was highly efficacious in rodents and therefore was widely 
anticipated to be a novel and extremely beneficial treatment for asthma 45.  While anti-
IL-5 largely reduced the number of eosinophils found in the bone marrow, blood, and 
sputum, tissue eosinophils were found to lack IL-5 receptor α and thus persisted despite 
treatment.  Ultimately, neutralization of IL-5 was unable to improve lung function 46-48. 
The IgE specific antibody omalizumab, or xolair, is one of the only approved 
therapeutics that attempts to directly target mast cell activation.  Omalizumab is a 
humanized IgE specific IgG1 antibody that can bind free IgE in the body and thus 
reduce its binding to FcεRI 49.  In response to reduced IgE binding mast cells and 
basophils will reduce FcεRI expression.  Thus the amount of IgE bound to the mast cell 
or basophil surface is dramatically decreased, so that upon allergen stimulation 
mediator release is largely reduced.  Over time the reduction of allergen induced 
mediator release alleviates asthma symptoms as well as the underlying airway 
inflammation associated with asthmatic disease 50.  However, recent concerns over the 
prevalence of xolair-induced anaphylaxis in long-term users have prompted an FDA 
investigation into the safety of this drug.  Additionally, xolair can cost over two thousand 
dollars each month depending on the dose required, making it too costly for many 
asthma sufferers 51.  Finally, symptoms are not alleviated immediately, and in fact once 
treatments begin it may take as long as sixteen weeks for optimal improvement of 
clinical symptoms to be observed 52.  Therefore, while omalizumab supports the theory 
that mast cell activation is an appropriate target for the treatment of asthma and allergic 
disease, there are still many challenges to its widespread use. 
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 Mast cells perform a complex function in asthmatic disease as their 
immediate mediator release can induce symptoms such as bronchoconstriction and 
mucus secretion while long-term cytokine production maintains chronic airway 
inflammation associated with disease 53.  Most current treatments attempt to block mast 
cell mediators subsequent to their release, only anti-IgE therapy with Xolair or mast cell 
stabilization with cromolyn-based therapeutics (i.e. Intal) are designed to prevent the 
release of inflammatory mediators altogether 54,55.  We have shown that the selective 
addition of derivatives allow fullerene compounds to specifically inhibit either mast cell 
degranulation or cytokine production, and in some cases both, thus allowing for the 
targeted inhibition of mast cell diseases.  Careful manipulation of these compounds may 
allow for more precise mast cell targeting and reduced toxicity, allowing us to determine 
their efficacy in the treatment of human disease 23,56. 
 
IV. Role of Eicosanoids 
 Eicosanoids are derivatives of arachidonic acid that perform a variety of 
functions.  These lipid signaling molecules are formed from arachidonic acid by one of 
three distinct metabolic pathways: the cyclooxygenase (COX) pathway, lipoxygenase 
(LOX) pathway, or cytochrome P-450 monooxygenase pathway 57,58.  Products of the 
COX pathway include the prostaglandins and thromboxanes, while the LOX pathway 
produces the cysteinyl leukotrienes, lipoxins, and some midchain 
hydroxyeicosatetraenoic acids (HETEs).  These two pathways are well studied, and 
both prostaglandins and leukotrienes have been shown to play a role in asthma as they 
can induce bronchoconstriction.  Specific inhibitors have been discovered and used 
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therapeutically to counteract these molecules.  Non-steroidal anti-inflammatory drugs, or 
NSAIDs, specifically inhibit the COX pathway and inhibit any downstream effects of the 
prostaglandins and thromboxanes 57.  The lipoxygenase pathway has multiple points of 
inhibition as Zileuton blocks the activity of 5-lipoxygenase, thus blocking leukotriene 
formation, while montelukast blocks the receptor for the cysteinyl leukotrienes, 
CysLT1
59.  Comparatively, products of the cytochrome P-450 pathway, which include 
the HETEs and cis-epoxyeicosatrienoic acids (EETs) (Figure 2), are not as well 
studied.  The HETEs and EETs function in several organ systems and both pro- and 
anti-inflammatory activities have been described58.  Inhibitors of the P-450 pathway do 
exist, but are not well characterized in vivo.  They include compounds that inhibit the 
formation of EETs, such as 6-(2-Propargyloxyphenyl) hexanoic acid (PPOH) and 
structural analogs such as 14,15-EE-5(Z)E that diminish their function 60.  There are 
currently no therapeutics that target this pathway. 
 Eicosanoids including LTC4, LTD4, PGF2α, and TXA2 worsen asthma 
pathogenesis by inducing bronchoconstriction.  However, not all eicosanoids are purely 
pro-inflammatory.  For example, PGE2 is a bronchodilator and can perform anti-
inflammatory functions in the lung 61,62.  Similarly, EETs have been shown to have anti-
inflammatory activity in the airways.  Specifically, they have been shown to relax 
histamine pre-contracted guinea pig bronchi63 and decrease levels of cell adhesion 
molecules including vascular adhesion molecules-1 (VCAM-1), E-selectin, and 
intercellular adhesion molecule-1 (ICAM-1) after cytokine upregulation 63-65.  This 
implies the EETs may play a role in dampening airway inflammation and 
bronchoconstriction, although this function has never been explored in vivo.  Thus, the 
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EETs may be previously unrecognized modulators of airway inflammation and 
bronchoconstriction in vivo. 
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Figure 2. Structure of HETE and EET, products of the cytochrome P-450 
metabolic pathway. 
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V.  Dissertation Objective 
While native fullerenes are impractical therapeutic options due to their insolubility 
in aqueous solutions, their derivitization can produce beneficial biological activities.  
Initial studies showed specifically derivatized C70 compounds capable of inhibiting mast 
cell degranulation and cytokine production.  It was our hypothesis that these 
compounds would inhibit mast cell driven disease by a mast cell dependent mechanism. 
Thus, the objective of this dissertation was to characterize fullerene action in vivo, 
primarily observing their action in mast cell driven disease.  In order to examine the 
biological action of derivatized fullerene C70 compounds in vivo, models of allergic 
asthma and anaphylaxis were developed and asthma parameters including airway 
inflammation and bronchoconstriction were assessed. 
As derivatized fullerene compounds are a new advancement, much controversy 
surrounds their safety and usefulness in the clinical setting.  Thus, once the efficacy of 
these compounds was established, a variety of studies examining their safety and 
mechanism of action were undertaken both in vivo and in vitro.   
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Materials and Methods 
I. Mice and Reagents  
Chicken egg ovalbumin (OVA), decamethonium bromide, and acetyl-β-methylcholine 
chloride (methacholine) were purchased from Sigma-Aldrich (St. Louis, MO). Aluminum 
hydroxide (alum) was purchased from Pierce (Rockford, IL).  Ketamine was purchased 
from Butler Schein (Dublin, OH) and xylazine was purchased from the department of 
animal resources (DAR) at VCU.  Fullerene C70-TGA was synthesized and tested at 
Luna Innovations Incorporated as described previously66.  LC/MS grade acetonitrile 
(A955-4), water (W6-4), iso-propanol (A461-4), formic acid (A117-50) were purchased 
from Fisher Scientific (Pittsburgh, PA). All deuterated standards were obtained from 
Cayman Chemicals (Ann Arbor, MI). The HPLC is a Shimadzu Prominance 20A series 
purchased from Shimadzu (Columbia, MD). The mass spectrometer was a 4000 
QTRAP from ABSciex (Foster City, CA).  C57BL/6 and Balb/c mice were purchased 
from Jackson Laboratory (Bar Harbor, ME).  Female mice aged 8-12 weeks were used 
in all experiments.  All mouse protocols were approved by the VCU Institutional Care 
and Use Committee. 
 
II. Mouse B cell purification and culture 
Murine B cells were purified from spleens by negative selection.  Single cell 
suspensions were obtained by pressing spleens between frosted glass slides.  T Cells 
were depleted by labeling with anti-CD5 (Ly-1), anti-CD8 (Ly-2), and anti-Thy1.1 (TiB99) 
followed by incubation with guinea pig complement (Harlan, Indianapolis, IN) and Mar 
18.5 (mouse anti-rat kappa) added to enhance complement activation.  Ly-1 and Ly-2 
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producing hybridomas were originally obtained from William Paul (NIH, Bethesda, MD).  
Remaining spleen cells were layered over a discontinuous percoll gradient using 50, 60, 
66, and 70% percoll (GE Healthcare) to separate B cells by density.  Resting B cells 
were recovered from the 66/70% interface.  The resting population was 80-90% B220+ 
as determined by flow cytometry.  B cells were cultured in complete culture medium.  To 
examine IgE production, resting B cells were cultured in 96 well plates (Corning Life 
Sciences, Lowell, MA) at varying concentrations (750 -50,000 cells/well) in 200 ul 
cRPMI containing 10,000 U/ml recombinant mouse IL-4 (kindly provided by William 
Paul), 25 ng/ml mouse CD40LT, and 100ng/ml M15 (anti-leucine zipper); fullerenes 
were added at varying concentrations (0.1, 1, 10 ug/mL) to treated wells.  Both CD40 
and M15 were generous gifts from Amgen, Seattle, WA.  Fullerenes were obtained from 
Luna Innovations, Incorporated (Danville, VA).  B cells were incubated for 8 days, at 
which time supernatants were harvested and analyzed by ELISA. 
 
III. Human B cell purification  
Human tonsils were obtained from routine tonsillectomies at Henrico Doctors Hospital 
(Richmond, VA) or the VCU TDAAC per approved IRB protocol. Tonsils were placed in 
RPMI-1640 and mechanically disrupted using a Seward Stomacher 80 Biomaster Lab 
Blender (Brinkmann, Westbury, NY) at normal speed for 60 seconds. To obtain a single 
cell suspension, the resulting product was underlayed with Ficoll–Hypaque (Amersham 
Pharmacia Biotech Inc., Piscataway, NJ) (30 ml diluted cells on 13 ml Ficoll–Hypaque 
solution). The tubes were centrifuged for 20 min at 400 × g. The cells were removed 
under the laminar flow hood, transferred to new tubes and washed in sterile PBS. 
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Assessment for total cell yield was done using Gentian Violet staining and viability using 
Trypan blue exclusion. To isolate B cells, the tonsilar preparation was incubated with an 
anti-human IgD conjugated with fluorescein isothiocyanate (FITC) (BD Pharmingen San 
Diego, CA) at a 1:1 ratio cells to antibody (1x106 cells/1µl Ab), and 1:9 ratio cells to 
buffer (1x106 cells/9µl buffer) for 30 minutes on ice in separation buffer (PBS with 0.25% 
BSA and 0.19% EDTA). Cells were then washed one time in full volume separation 
buffer to remove unbound antibody and then re-suspended at a 1:9 ratio cells to buffer 
(1x106 cells/9µl buffer), and 1:1 ratio (1x106 cells/1µl Ab) cells to anti-FITC Microbeads 
(Miltenyi Biotec Auburn, CA) and incubated again on ice for 30 minutes. Post secondary 
incubation, cells were re-washed in full volume separation buffer and isolated via the 
Miltenyi MACS cell separation protocol to obtain a >95% pure IgD+ B cell population.  
  
IV. IR800 Study 
To assess tissue distribution of fullerene compounds, Luna Innovations Inc. produced a 
fullerene C70 sphere coupled to IR-800 dye (C70-IR800).  Naïve mice were given 10 µg 
C70-IR800 i.n. and sacrificed at 4 hours, 24 hours, 96 hours, and 1 week following i.n. 
instillation.  Lung tissue was collected and the presence of IR-800 dye in whole lung 
tissue was measured using the Odyssey Infrared Imaging Sytem. 
 
V. Microarray analysis for CYP1B1 
Mast cells (1 x 107 cells per condition, each condition performed in triplicate) were 
incubated with or without fullerene derivatives at a concentration of 10 µg/ml for 16 
hours.  Cells were then incubated with or without anti-FcεRI antibodies for 10 minutes, 
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after which supernatants were removed (to remove preformed mediators) and fresh 
warm medium containing anti-FcεRI antibodies (1 µg/mL) added for 2 hours.  Cells were 
centrifuged and the supernatant and pellet were immediately frozen.  RNA was isolated 
using the Ambion MessageAmp aRNA kit (Applied Biosystems/Ambion, Austin, TX, 
USA); all samples passed the internal quality control checks.  Microarray was performed 
using the Human Whole Genome OneArrayTM gene expression profiling service 
(Phalanx Biotech Group, Palo Alto, CA, USA). 
 
VI. Passive Systemic Anaphylaxis Induction 
Female C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) aged 10-12 weeks were 
utilized.  In order to develop a mast cell dependent model of anaphylaxis, mice were 
passively sensitized by i.p. injection of 75 µg IgE-dinitrophenol (DNP) diluted in PBS.  
Two hours later mice were injected i.p. with C70-TGA or Inos (100 ng/200 µL in PBS), or 
200 µL PBS alone as a vehicle control.  After 16 hours, mice were challenged i.p. with 
100 µg DNP-BSA (Sigma-Aldrich, St. Louis, MO) in 100 µL PBS.  Body temperature 
measurements were recorded with a digital rectal thermometer every 10 minutes for a 
total of 50 minutes.  Peripheral blood was harvested by cardiac puncture and mixed with 
10 µl EDTA to prevent coagulation 50 minutes after antigen challenge.  Plasma 
histamine measurements determined by ELISA. 
 
VII. Murine Asthma Induction and tissue collection   
In the acute inflammatory model, mice were sensitized by injection of 0.5 mg OVA and 
4mg alum in PBS on days 0 and 13.  Ovalbumin and alum were injected i.p., 200μl per 
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injection.  On days 19, 22, and 27 Mice were challenged with 1% OVA in PBS 
aerosolized with an ultrasonic nebulizer for 45 minutes.  Mice were sacrificed on day 29, 
at which time bronchoalveolar lavage (BAL) fluid was collected by flushing the lungs 
with 1 mL PBS.   The BAL fluid was centrifuged and supernatant was saved for cytokine 
analysis.  Pelleted cells were resuspended in 100 µl PBS and spun onto slides, then 
stained with Hema 3 stain set (Fisher diagnostics, Middletown, VA).  Percentages were 
determined by counting at least 100 leukocyte cells per cytospin. Lung tissue was 
collected and fixed with 10% buffered formalin phosphate (fisher) and embedded in 
paraffin at the VCU pathology core.  Five µM sections were cut onto microscope slides 
and stained with hematoxylin and eosin (H&E).  A Nikon eclipse with a SPOT Flex 
Shifting Pixel Color Mosaic (Diagnostic Instrumental Inc., Sterling Heights, MI) camera 
was used to photograph lung sections. 
 
To induce non-allergic airway inflammation, mice were sensitized by injection of 0.1 mg 
OVA and 2 mg alum in PBS on days 1 and 8.  On days 14 to 20, Mice were challenged 
each day with 1% OVA in PBS aerosolized with an ultrasonic nebulizer for 45 minutes.  
Mice were sacrificed on day 21, BAL fluid and lung tissues were collected as above. 
 
To induce MC dependent asthma, mice were sensitized by injection of 10 µg OVA in 
saline every other day for 13 days.  Ovalbumin was injected i.p. in 100 µl saline solution.  
On days 40, 43, and 46 after the initial sensitization mice were challenged i.n. with 200 
µg OVA in 20 µl saline.  On day 47 mice were sacrificed, BAL fluid and lung tissues 
were collected.  A modified version of this protocol that induces milder inflammation was 
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utilized to assess bronchoconstriction.  In this model, mice were sensitized by injection 
of 50 µg OVA on days 1, 3, 5, and 7 and then challenged on days 22, 25, and 28 with 
200 µg OVA in saline.  Mice were sacrificed on day 29 and AHR was assessed using 
the Flexivent system (Scireq, Montreal, QC, Canada).  Mice were anesthetized by i.p. 
injection of approximately 200 mg/kg ketamine and 40 mg/kg xylazine.  Once 
unresponsive a 19 gauge blunt end cannula was inserted into the trachea and 
ventilation began immediately.  Following cannulation mice were paralyzed by i.p. 
injection of 0.5 mg decamethonium bromide.  Mice were ventilated at a frequency of 2 
breaths per second and a tidal volume of 2 x 107 m3 and positive end-expiratory 
pressure of 3 cmH20.  Lung function was assessed once it was determined that 
breathing was completely by mechanical ventilation.  Responsiveness to methacholine 
was determined by exposing mice aerosolized PBS and then to increasing doses (10, 
25, 50, 100 mg/ml) of methacholine.  Each aerosol was delivered for 10 sec and 
resistance was measured every 6 seconds following aerosol challenge for a total of 3 
minutes.  The maximum airway resistance in response to each methacholine dose was 
determined by averaging the three highest values. 
 
VIII. Established asthma induction   
To induce established asthma, mice were sensitized by injection of 10 µg OVA in saline 
every other day for 13 days and challenged i.n. on days 40, 43, and 46 with 200 µg 
OVA in 20 µl saline.  Treatment with 20 µg C70-TGA began on day 46 and continued 
every three days following.  Mice were challenged again with 200 µg OVA i.n. on days 
66, 69, 72, and 75.  On day 76 mice were sacrificed and BAL fluid was collected.  Lung 
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tissues were fixed in 10% buffered formalin phosphate for 24 hours, then sectioned and 
stained with H&E. 
 
IX. Quantitative analysis of eicosanoids via HPLC ESI-MS/MS 
BAL fluid was clarified by centrifugation at 15,000 g for 10 minutes. To 300 μl of the 
clarified fluid 300 μl of ethanol is added together with 10 ng each deuterated PGE2, 
PGD2, 6ketoPGF1α, 5HETE, 15HETE, 14,15EET, LTB4, LTC4, LTD4, LTE4, 
arachidonic acid and eicosapentaenoic acid as internal standards. 10 μl of this mixture 
was resolved in a 30 minute reversed-phase HPLC method. A Kinetex C18 column (100 
x 2.1mm, 2.6µ) was used to separate the eicosanoids at a flow rate of 200 µl/min at 
50°C.  Prior to sample injection, the column was equilibrated with 100% Solvent A 
[acetonitrile:water:formic acid (40:60:0.02, v/v/v)].  100% Solvent A was used for the first 
minute of elution.  Solvent B [acetonitrile:isopropanol (50:50, v/v)] was increased 
following a linear gradient to 25% Solvent B by 3 minutes, to 45% between 3 and 11 
minutes, to 60% between 11 and 13 minutes, to 75% between 13 and 18 minutes, and 
to 100% between 18 and 20 minutes.  The gradient was maintained at 100% Solvent B 
from 20 to 25 minutes, and was then decreased to 0% by 26 minutes, and held at 0% 
until 30 minutes.  The eluting eicosanoids were analyzed using an inline hybrid linear 
ion trap triple quadrapole tandem mass spectrometer (ABI 4000 Q-Trap®, Applied 
Biosystems) equipped with an electrospray ionization source operating in negative ion 
multiple-reaction monitoring mode.  Eicosanoids were monitored using relevant 
precursor → product MRM pairs.  Additional mass spectrometric parameters used are 
as follows: Curtain Gas: 30; CAD: High; Ion Spray Voltage: -3500V; Temperature: 
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500°C; Gas 1: 40; Gas 2: 60; Declustering Potential, Collision Energy, and Cell Exit 
Potential vary per transition. 
 
X. ELISA and multiplex cytokine assay  
Muc5AC protein was measured by ELISA, as described by Takeyama et. al.67  
Bronchoalveolar lavage fluid was diluted to several concentrations with PBS, and 75 µl 
of each sample was incubated with bicarbonate-carbonate buffer (75µl) at 40° in a 96 
well plate (Nunc) for a total volume/well of 150µl until dry.  Plates were washed three 
times with PBS and blocked with 2% BSA (Sigma) for 1 hour at room temperature.  
Plates were again washed three times with PBS, then incubated with 50µl mouse 
monoclonal Muc5AC antibody(Pierce) (1:100), diluted with PBS containing 0.05% 
Tween 20, for one hour.  Plates were washed three times with PBS and 100µl 
horseradish peroxidase-goat anti-mouse IgG conjugate (1:10,000) diluted in blocking 
solution was added to each well.  Following one hour incubation, plates were then 
washed three times with PBS.  Color reaction was developed with 3,3’,5,5’-
tetramethylbenzidine (TMB) peroxidase solution (BD Bioscience) and stopped with 
0.18M H2SO4.  Abosrbance was read at 450 nm.  Cytokine levels in the BAL fluid were 
measured using a multiplex cytokine assay (Biorad, Hercules, CA) according to the 
manufacturer’s instructions.   
Total mouse IgE was measured as described previously68.  Briefly, IgE levels in 
mouse serum were determined by coating ELISA plates with 10 ug/ml B1E3, a rat anti-
mouse IgE mAb.  Standard curves were generated with mouse IgE anti-DNP beginning 
at a concentration of 1000 ng/ml and serially diluted across the plate.  IgE levels were 
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detected by incubation with R1E4, a rat anti-mouse IgE mAb, followed by streptavidin-
AP.  Plates were developed using pNPP substrate tablets diluted in substrate buffer and 
read at a dual wavelength of 405-650 nm. 
The liver enzymes aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were measured as described previously 69.  Serum creatinine 
levels were measured according to manufacturer’s instructions (Arbor Assays, Ann 
Arbor, MI). 
 
XI. Statistical Analysis 
P-values were calculated using unpaired two-tailed Student’s t-tests for data following a 
Gaussian distribution or an unpaired two-tailed Mann-Whitney test for data that did not 
follow a Gaussian distribution.  A one-way analysis of variance (ANOVA) test was used 
when three or more groups were compared.  Error bars represent standard error of the 
mean between samples.  * indicates p<0.05 and ** indicates p<.01. 
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Results 
I.  Fullerene C70 Derivatives inhibit mast cell and B cell responses in vitro 
While native fullerenes have been studied extensively in vitro, their derivatized 
counterparts have varying levels of biological activity and toxic potential and thus each 
compound must be characterized independently.  Before progressing to lengthy in vivo 
studies, fullerene derivatives were examined in vitro for their ability to inhibit the actions 
of mast cells and B cells, which are of interest for their role in allergic disease. 
A. Effect of Fullerene C70 derivatives on mast cell degranulation and 
cytokine production.  In order to examine the biological activity of specifically 
derivatized fullerene compounds, a panel of fullerene derivatives were developed and 
characterized by Luna Innovations, Incorporated (Danville, VA).  Each of these 
compounds consisted of a fullerene core (C60 or C70) with differing chemical moieties 
attached, making them compatible with aqueous systems.  These compounds were 
then analyzed in vitro to assess biological activity by examining their ability to inhibit 
degranulation (Figure 3A) and cytokine production (Figure 3B) by human skin mast 
cells.  Beta-hexosaminidase is released when mast cells degranulate, and this mediator 
can be measured in the supernatants from cultured cells in order to quantitate the 
extent of mast cell degranulation.  Of the fullerene compounds examined, several were 
able to dampen beta hexosasaminidase release.  One of the best inhibitors was the 
compound C70-tetraglycolate, or C70-TGA, which inhibited beta-hexosaminidase release 
by greater then 40%.  Additionally, C70-TGA pretreatment reduced TNF-α production by 
approximately 40% and GM-CSF production by 60% (Figure 3B).  As C70-TGA was 
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Figure 3. In a panel of fullerene derivatives, C70-TGA is one of the best inhibitors 
of mast cell function. Human skin mast cells were incubated overnight with or without 
fullerenes, then stimulated with an anti-FcεRI antibody, 3B4.   (A) Supernatants were 
collected for Beta-hexosaminadase 30 minutes later.  (B) Supernatants were collected 
for cytokine analysis 24 hours after 3B4 stimlation TNF-α (dark gray bars) and GM-CSF 
(light gray bars).  
A. 
B. 
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best able to inhibit all aspects of the mast cell response in vitro, this compound was 
chosen for further in vitro and in vivo studies to assess biological activity and its effect 
on mast cell driven disease.  Shown in Figure 4, C70-Tetraglycolate was created by the 
addition of four glycolic acids to the fullerene C70 core.  This compound was used in the 
majority of the studies discussed here. 
B.  Effect of C70-Tetraglycolate and murine B cells in vitro.  Because B cells 
also play a role in mast cell mediated diseases such as asthma and other allergic 
diseases, the effect of C70-TGA on B cells was also assessed in vitro prior to attempting 
in vivo studies (Figure 5).  Specifically, B cells function in allergic responses by 
producing large amounts of allergen specific antibodies, with IgE being most commonly 
associated with allergic disease.  Murine B cells isolated from the spleen were pre-
treated with or without C70-TGA, then activated with IL-4 and CD40 ligand.  In the 
presence of as little as 1µg/mL C70-TGA, B cell IgE production was moderately reduced 
(Figure 5).  B cells activated in the presence of 10 µg/mL C70-TGA almost completely 
eliminated production of IgE (Figure 5).  To be sure that this effect was not merely the 
result of fullerene toxicity, viability of B cells treated with C70-TGA was assessed (Figure 
6) using propidium iodide staining.   Fullerene treated B cells were compared to those 
left untreated and to B cells treated with a non-toxic antioxidant, ascorbic acid.  Viability 
was assessed for the first five days following B cell isolation because after this time 
viability is largely reduced regardless of treatment.  A dose of 1 µg/mL C70-TGA had no 
effect on B cell viability, as these cells were just as viable as untreated or ascorbic acid 
treated B cells (Figure 6A).  However, the higher 10 µg/mL dose of C70-TGA greatly 
reduced B cell viability starting at day 4, as indicated by the large increase in PI+  
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Figure 4. C70-Tetraglycolate (C70-TGA). Formed by the addition of four glycolic acids 
to the fullerene C70 core, this compound was used in all studies unless otherwise stated. 
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Figure 5. C70-TGA reduces IgE production by B cells in vitro.  Murine B cells were 
isolated from the spleen.  B cells were activated with CD40 ligand and IL-4 in the 
presence or absence of C70-TGA.  Cells were incubated for 8 days in order to allow for 
B cell proliferation and class switching.  At the end of this time, supernatants were 
collected and IgE ELISA was performed. P-values were determined using an unpaired 
two-tailed student t-test. 
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Figure 6.  C70-TGA reduces B cell viability at high doses in vitro.  Murine B cell 
viability was assessed every day for 5 days of incubation with C70-TGA.  Each day, 
cultured B cells were washed and stained with propidium iodide.  The percentage of PI+ 
cells was determined using a FACS cytometer. 
A. 
B. 
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stained cells (Figure 6B).  Therefore, the significant reduction in IgE production seen in 
Figure 5 following treatment with 10µg C70-TGA was most likely due to B cell death 
rather than an inhibitory mechanism of the C70-TGA.  Still, these results were promising 
as even a low dose of C70-TGA that is incapable of affecting B cell viability was able to 
moderately reduce IgE production, an effect that could potentially modulate and even 
reduce disease pathogenesis in vivo.  Results were similar in human B cells isolated 
from tonsils, where C70-TGA was able to significantly, but not completely, reduce IgE 
production (Figure 7).  Data shown are representative as there is much more variability 
in human samples, but displays the trend that was seen in the majority of human 
tonsillar B cell samples.  Because C70-TGA significantly inhibits mast cell and B cell 
function in vitro, we decided to examine the effect of C70-TGA on mast cell driven 
allergic disease utilizing murine models of anaphylaxis and asthma.   
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Figure 7. C70-TGA reduces IgE production by human tonsillar B cells.  Human B 
cells were isolated from tonsils obtained from routine tonsillectomies.  B cells were 
incubated with 0.1, 1, or 10 µg/mL C70-TGA then activated with anti-CD40 and IL-4 for 8 
days.  Supernatants were collected and IgE levels were measured by ELISA.  Data 
shown are representative as variability between patients is high.  ** = p<.01 and  *** = 
p<.001 using unpaired two tailed student t-test. 
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II. C70-Tetraglycolate, a specifically derivatized fullerene compound, reduces 
pathogenesis of allergic asthma and anaphylaxis in vivo 
 Previous work showed that non-specific fullerene C60 compounds can inhibit 
mast cells in vitro by entering the cell and directly affecting expression of signaling 
molecules 70.  Specifically, fullerenes were shown to dramatically reduce 
phosphorylation of Syk, a kinase associated with FcεRI receptor signaling.  Further, C70-
TGA was shown to inhibit the release of intracellular calcium stores, which is induced 
upon FcεRI crosslinking66.  This could explain, at least in part, why degranulation is 
reduced in the presence of C70-TGA. Because fullerenes, and particularly C70-TGA, 
seem to have mast cell targeted effects in vitro, we anticipated this compound would 
have the greatest in vivo effect in heavily mast cell influenced models of disease.  
 Using a passive systemic anaphylaxis model we were able to directly examine 
the effect of C70-TGA on the mast cell response in vivo as passive sensitization focuses 
this response around mast cell function, bypassing other immune cells involved in 
allergic response.  We further characterized the in vivo activity of C70-TGA using various 
models of asthmatic disease.  These models incorporate active sensitization, allowing 
us to view the overall immune response to C70-TGA. 
A. Effect of C70-TGA in a passive systemic anaphylaxis model.  A passive 
systemic anaphylaxis model was used to examine the in vivo effect of C70-TGA on the 
mast cell response.  Anaphylaxis is not generally dependent solely on mast cell function 
as it is an allergic response to allergen and thus many immune cells are involved.  
Injection of allergen specific IgE passively sensitizes mice, immediately preparing mast 
cells for a reaction against allergen.  Passive sensitization involved injecting mice with 
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DNP-specific IgE followed by i.p. injection with C70-TGA two hours later so as not to 
interrupt binding of IgE to its receptor, FcεRI.  Mice were then challenged with DNP-
albumin 16 hours after IgE sensitization, causing a systemic anaphylactic response in 
which sensitized mast cells released mediators such as histamine and leukotrienes and 
caused the animal’s body temperature to drop.  Severity of this response was measured 
by recording the change in body temperature (Figure 8) and quantitating plasma 
histamine levels (Figure 9).  By 30 minutes post-challenge the body temperature drop 
commonly associated with anaphylaxis was drastically reduced in C70-TGA pre-treated 
animals.  Significant improvement in body temperature was seen at 40 and 50 minutes, 
compared to animals that had not been given C70-TGA.  Mice were sacrificed 50 
minutes post-challenge and blood was collected for quantitation of plasma histamine 
levels.  Corresponding to body temperature reduction, plasma histamine levels were 
also significantly reduced in C70-TGA treated animals.  This reduction was seen only in 
animals given C70-TGA, which specifically inhibited mast cell degranulation and cytokine 
production in vitro (Figure 9, light gray middle bar), and not in animals treated with non-
specific fullerene compounds (Figure 9, dark gray right bar). 
 B.  Effect of C70-TGA in a model of allergic asthma.  In order to further 
examine the inhibitory capabilities of C70-TGA in vivo, its therapeutic efficacy was 
examined in a murine model of allergic asthma.  Because prior experimentation 
suggested that C70-TGA may exert its inhibitory effects primarily on mast cells, a heavily 
mast cell-influenced  
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Figure 8.  C70-TGA prevents the drop in body temperature associated with 
systemic anaphylaxis.  Mice were passively sensitized with 75 µg DNP-IgE i.p., then 
injected i.p. with 2 µg C70-TGA in PBS or 100 µl PBS alone two hours following IgE 
injection.  Mice were challenged with DNP-BSA 16 hours later and body temperature 
was recorded every 10 minutes.  P-values were determined using an unpaired two-
tailed student t-test.  N= 5 mice per group. 
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Figure 9. C70-TGA significantly reduced serum histamine levels following 
induction of passive systemic anaphylaxis. Mice were treated as described in Figure 
8. Fifty minutes after antigen challenge, mice were sacrificed and blood was collected 
via cardiac puncture.  Plasma histamine levels were quantitated by ELISA, as described 
in materials and methods.  Black bar represents mice treated with vehicle control (PBS), 
dark gray bar represents mice treated with a non-inhibitory control fullerene, and light 
gray bar represents mice treated with C70-TGA.  P-values were determined using an 
unpaired two-tailed student t-test.  N = 5 mice per group. 
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model was selected.  This model (Figure 10) was developed and tested by Dr. Stephen 
Galli’s laboratory, and a previous publication characterizing it finds mast cell deficient 
mice are much less susceptible to disease, exhibiting significantly reduced levels of 
airway inflammation and bronchoconstriction following antigen challenge71.  This is due, 
at least in part, to the elimination of adjuvant from the sensitization process.  Treatment 
with C70-TGA began one day prior to the initial sensitization injection, and continued 
every three days throughout the course of the experiment.   This dosing regimen was 
decided based on localization studies using a dye conjugated C70-TGA compound.  
Specifically, C70-TGA was conjugated to an IR-800 dye molecule (IR800-C70-TGA) 
which can be visualized with the Odyssey infrared imaging system.  Using this method, 
whole organs can be excised from an animal and imaged to observe localization of the 
dye compound.  When C70-TGA localization was observed by this method, the 
compound had a strong presence in the lung 4 hours after i.n. instillation, but began to 
dissipate out by 24 hours (Figure 11).  Ninety-six hours after i.n. instillation, C70-TGA 
was completely removed from the lung.  While we wanted C70-TGA to be present in the 
lung throughout asthma induction, we also wanted to avoid toxic build-up of the 
compound that could have other effects on the mice.  Thus, we chose to dose the mice 
every three days, allowing enough time for the compound to be mostly removed from 
the lung but still present long enough to assess the effect on asthma pathogenesis. 
Mice were sensitized and challenged with OVA in saline and on day 47, mice 
were sacrificed and airway hyperresponsiveness was assessed, and bronchoalveolar 
lavage (BAL) fluid and lung tissue were collected for further analysis.  The BAL fluid was 
collected by flushing the lungs with 1 mL PBS, allowing us to collect a sampling of cell
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Figure 10. Mast cell influenced model of allergic asthma.  In this model, mice are 
sensitized by i.p. injection of 10 µg OVA in saline every other day for two weeks, then 
challenged with 200 µg OVA in saline at 40, 43, and 46 days after the initial injection.  
On day 47, mice are sacrificed and airway hyperresponsiveness (AHR) is assessed, 
bronchoalveolar lavage (BAL) and lung tissue are collected for further analysis.  
Treatment with C70-TGA began one day prior to the initial sensitization injection and 
continued every three days throughout the experiment.  Each mouse was given 20 µg 
C70-TGA  i.n. on each treatment day.  Mice were also bled prior to initiating 
sensitization, after sensitization, and once again two days prior to sacrifice.   
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Figure 11. Localization of IR800-C70-TGA in lung tissue. IR-800 dye conjugated C70-
tetraglycolate was delivered to the lung i.n. and allowed to disseminate for various 
amounts of time.  At each time point, a mouse was sacrificed and lungs were excised 
and staining visualized using the Odyssey infrared imaging system.  A control mouse 
given no C70-IR800 represents background staining. 
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types and cytokines present in the lung.  Total cells in the BAL fluid were counted, spun 
onto slides and stained with Hema 3 stain, a combination of eosin and methylene blue 
dyes.  This allowed for the differentiation of eosinophils from other cell types as these 
cells take up the eosin dye and are thus dyed a pinkish-blue color (Figure 12).  As 
shown in these representative photographs, eosinophils and other immune cells are 
relatively abundant in mice given PBS i.n. while these cells are virtually absent in 
animals that received i.n. C70-TGA treatment. 
Immune cells in the BAL were distinguishable based on staining and morphology.  
Therefore, we were able to count the number of eosinophils in the BAL as a percentage 
of total immune cells.  Doing this, we found the percentage of eosinophils is significantly 
reduced in C70-TGA treated mice when compared to those given PBS treatment (Figure 
13).  Using this percentage and total cell counts that were done prior to slide 
preparation (Figure 14A), the total number of eosinophils in each BAL sample was 
extrapolated.  Not surprisingly, total eosinophil numbers are also significantly reduced in 
C70-TGA treated animals (Figure 14B).  In fact, total eosinophil numbers in C70-TGA 
treated animals are quite similar to those seen in our non-sensitized controls, 
suggesting that disease pathogenesis is significantly altered in these animals.  Total 
cellular infiltration of the lung is also significantly reduced, as indicated in Figure 14A by 
the significant reduction in total BAL cell counts seen in C70-TGA treated mice.  Taken 
together, these data indicate that local administration of C70-TGA significantly dampens 
lung inflammation associated with allergic asthma in vivo. 
To further assess lung inflammation, whole lungs were sectioned and stained 
with hematoxylin and eosin (H&E stain).  This staining reveals cellular infiltration of the  
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Figure 12. Cell types found in the BAL fluid.  Bronchoalveolar lavage cells were spun 
onto slides and stained with Hema 3 stain kit.  Immune cells can be distinguished based 
on staining and morphology.  Representative photographs are shown. 
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Figure 13. C70-TGA significantly inhibits the percentage of eosinophils observed 
in the BAL fluid.  Mice were treated using the model shown in figure 10.  On day 47, 
animals were sacrificed and BAL fluid was collected by flushing the lungs with 1 mL 
PBS.  Cells in the BAL were spun onto slides and stained with Hema 3 stain set.  
Inflammatory cells found in the BAL fluid were counted and eosinophils are represented 
as a percentage of total inflammatory cells.  Results are significant using one-way 
analysis of variance and student t-test test.  N = 6-10 animals per group.   
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Figure 14. C70-TGA significantly inhibits the total number of cells infiltrating the 
airways.  Mice were treated using the model shown in Figure 10.  Cells in the BAL fluid 
were quantitated by trypan blue exclusion.  Total eosinophil numbers were extrapolated 
using percentages observed in Figure 13.  Non-sensitized (NS) controls are shown for 
reference.  n = 6-10 animals per group.  * = p<.05 or ** = p<0.001 as determined by 
student t-test and one-way analysis of variance. 
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lung tissue and allows us to identify areas of inflammation.  In mice treated with PBS, 
several large areas of inflammation are seen, as indicated by arrows (Figure 15).  In 
contrast, only small areas of mild inflammation can be seen in mice treated with C70-
TGA.  In fact, lungs of C70-TGA treated animals look similar to non-sensitized mice, with 
minimal inflammation and airway thickening.  Moreover, within areas of inflammation 
PBS treated mice contain more eosinophils then are found in C70-TGA treated animals 
(Figure 16).  Together, these data indicate that C70-TGA strongly reduces cellular, and 
specifically eosinophil, infiltration into the lung following allergic airway challenge. 
 Because mucus overproduction is a major contributor to death in cases of fatal 
asthma72, lung sections were also stained with periodic acid-Schiff (PAS) to assess 
mucus production in the airways of OVA-challenged mice.  This stain reacts with 
glucose and other sugars, creating a purple-magenta color.  It is commonly used to 
identify mucus production in tissues.  Periodic acid-Schiff staining is reduced in C70-TGA 
treated animals compared to those given PBS alone (Figure 17), although no difference 
was seen in Muc5AC protein in the lung tissue (Figure 18). 
 Currently, therapeutics are available to treat either airway inflammation or 
bronchoconstriction, but none have been successful at treating both symptoms of 
disease.  Therefore, combination therapies including both corticosteroids (to treat 
inflammation) and a bronchodilator (to treat bronchoconstriction) are generally given.  
Developing a therapeutic capable of inhibiting both airway inflammation and  
bronchoconstriction would be very unique, so we examined whether C70-TGA was 
capable of such inhibition.  To examine bronchoconstriction in this model, the flexivent 
system was utilized.  The flexivent measures airway constriction through an invasive  
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Figure 15.  Lung sections show cellular infiltration of airways.  Lung tissue was 
fixed in 10% formalin, sectioned, and stained with H&E.  Representative photographs 
are shown, taken at 10X magnification.  Arrows indicate areas of inflammation. 
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Figure 16.  Lung sections show eosinophils infiltrating airways.  Lung tissue was 
fixed in 10% formalin, sectioned, and stained with H&E.  Representative photographs 
are shown, taken at 100X magnification.  Arrows indicate eosinophils. 
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Figure 17.  PAS staining in C70-TGA treated mice shows reduced mucus 
production.  Lung tissue was fixed in 10% formalin, sectioned, and stained with PAS.  
Representative photographs are shown, taken at 20X magnification.  Bar measures  
100 µm. 
PBS 
TGA 
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Figure 18. C70-TGA does not alter Muc5AC protein levels in bronchoalveolar 
lavage fluid.   Mice were treated as indicated in Figure 10.  Bronchoalveolar lavage 
fluid was collected on day 47 and Muc5AC was measured by ELISA.  N= 6 mice per 
group.  Student t-test and analysis of variance were used to test for significance. 
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method, where tracheotomy is performed and a cannula inserted directly into the 
trachea in order to measure levels of constriction.  Airway response to increasing doses 
of methacholine was measured, and what we found was rather intriguing.  
Tetraglycolate was able to significantly inhibit bronchoconstriction in mice (Figure 19), 
suggesting that the mechanism of C70-TGA inhibition is different than other therapeutics 
currently available.  Many of the PBS treated animals died after receiving higher doses 
of methacholine due to severe airway constriction.  In contrast, C70-TGA treated animals 
seemed to fare much better (Figure 20).  Several of the C70-TGA treated animals 
survived to the highest dose of methacholine, just like their non-sensitized counterparts.  
This suggests that the reduction in airway constriction induced by C70-TGA has 
functional relevance, and opens up a new set of questions regarding the action of C70-
TGA. 
 In human patients, asthma is diagnosed only after symptoms become evident, 
and therefore therapeutics are given after disease has been established.  While 
preliminary studies established efficacy of C70-TGA in the treatment of asthma, 
experiments where C70-TGA was given throughout sensitization and challenge are not 
the best models for human disease.  Therefore a model of established disease was 
developed, where airway inflammation and bronchoconstriction develop prior to C70-
TGA treatment.  In this model (Figure 21), mice were sensitized and challenged as in 
the previous model.  Because this model had been performed several times, we know 
the animals have severe airway inflammation and bronchoconstriction following this first 
set of allergen challenges.  Following this initial set of challenges, i.n. C70-TGA 
treatments were given over a 20 day period.  As before, animals were given 20 µg C70-  
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Figure 19. C70-TGA treatment significantly reduces bronchoconstriction.  Mice 
were treated as indicated in Figure 10.  On day 47, a cannula was placed in the trachea 
and airway resistance was measured in response to increasing doses of methacholine 
using the flexivent system.  N = 6-10 animals per group.  * = p<.05 using unpaired two 
tailed student t-test. 
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Figure 20. C70-TGA rescues mice from methacholine induced death.  Mice were 
treated as indicated in figure 10.  On day 47, airway resistance was measured in 
response to methacholine. When airway constriction was severe enough to cause 
death, the dose at which death occurred was recorded and survival is plotted.  N = 6 
mice per group. 
 
 
 
 
 
 
0 25 50 75 100
0
25
50
75
100
125
Non-Sensitized
PBS
TGA
Methacholine dose (mg/ml)
P
e
rc
e
n
t 
s
u
rv
iv
a
l
  
50 
 
 
 
 
Figure 21. Model of established asthma in mice.  Mice are sensitized and challenged 
as described in Figure 10.  C70-TGA treatment begins on day 47, following the initial 
allergen challenge.  Treatments continue for a twenty day period, 20 µg per mouse is 
given i.n. every three days.  A second set of allergen challenges begins on day 66, 
where 200 µg OVA is given i.n. every three days.  Following this second set of 
challenges, mice are sacrificed on day 76 and airway hyperresponsiveness is assessed, 
BAL fluid and lung tissues were collected for analysis. 
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TGA every three days during this time.  Another four allergen challenges were given 
after the 20 day treatment period in order to re-initiate asthma pathogenesis.  Mice were 
sacrificed after this secondary set of allergen challenges, and again airway inflammation 
and bronchoconstriction were assessed. 
Immune cells in the BAL fluid were counted and the percentage of each cell type 
was recorded (Figure 22).  Even when airway inflammation was already established in 
mice, C70-TGA treatment was able to significantly reduce eosinophil infiltration into the 
airways.  Lymphocyte infiltration was increased in C70-TGA treated mice over what was 
seen in the controls, but the percentage lymphocytes in C70-TGA treated animals was 
not significantly different from PBS treated animals, and so probably represents 
variability 
between mice.  Lung tissues sectioned and stained with H&E showed a vast reduction 
in cellular infiltration into the lungs of C70-TGA treated animals (Figure 23).  Thus, C70-
TGA is capable of significantly reducing existing allergic airway inflammation in the lung. 
 While inhibition of airway inflammation is very important, the ability to inhibit both 
airway inflammation and bronchoconstriction would make C70-TGA a very unique 
compound.  However, assessing bronchoconstriction in the established model of 
asthma was complicated as the secondary challenge caused severe airway constriction 
in these mice, sometimes leading to death after minimal methacholine stimulation.  In 
those mice that survived to higher doses of methacholine, C70-TGA treated animals 
tended to have lower airway resistance compared to those treated with PBS (Figure 
24).  While this data did not reach significance, it suggests that C70-TGA may at least 
have some effect on bronchoconstriction in mice treated after disease establishment. 
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Figure 22. C70-TGA significantly reduces eosinophilia when given after initial OVA 
challenge.  Asthma was induced as shown in Figure 21.  Cells in the BAL fluid were 
stained with Hema 3 stain set.  Inflammatory cells in the BAL were counted and 
macrophages, lymphocytes, eosinophils and neutrophils are represented as a 
percentage of total inflammatory cells. P-values were determined by unpaired two-tailed 
student t-test.  N = 11-12 animals per OVA sensitized group, 3 non-sensitized controls. 
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Figure 23. C70-TGA severely dampens lung tissue inflammation in an established 
model of asthma.  Lung tissue was fixed in 10% formalin, sectioned, and stained with 
H&E.  Bar measures 100 µm.  Representative photographs are shown. 
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Figure 24. C70-TGA dampens bronchoconstriction when given after initial OVA 
challenge.  Asthma was induced as shown in Figure 21.  Airway resistance in response 
to increasing doses of methacholine was measured using the flexivent system.  N= 4-6 
mice per group. 
 
 
 
 
 
 
 
 
 
 
  
55 
 
C. Effect of C70-TGA on non-allergic airway inflammation.  All experiments 
described thus far utilized a model in which the development of airway inflammation and 
bronchoconstriction depended on mast cell function.  This is generally the best model 
for human disease, as mast cells are known to play a role in asthma pathogenesis and 
are abundant in the airways of asthmatic patients 72,73 .  However, not all asthma is 
allergic in nature, although eosinophil infiltration is the cornerstone of both allergic and 
non-allergic disease74.  Non-allergic asthma tends to be more severe and is often 
corticosteroid refractory.  While these patients do have high levels of circulating IgE, it is 
not allergen specific, and patients have negative skin-prick tests75. 
In order to further characterize C70-TGA function, its efficacy was examined in 
two models of non-allergic disease in which severe inflammation and 
bronchoconstriction is observed.  In these models, mice are sensitized with ovalbumin 
and the adjuvant aluminum hydroxide, inducing a more severe immune response.  The 
first of these models employs two i.p. OVA sensitizations followed by a week-long 
break, then three airway challenges with 1% aerosolized ovalbumin (Figure 25).  
Previous research in our laboratory has found this model is IgE dependent, as 
eosinophilia is not induced in IgE knockout mice76,77, but mast cell independent, as 
eosinophilia is induced in mast cell deficient W/Wsh mice76 (data not shown).   
 In order to assess C70-TGA efficacy in this model of asthmatic disease, mice 
were given i.n. C70-TGA treatments throughout sensitization and challenge.  On day 29, 
mice were sacrificed and eosinophilia was assessed.  In C70-TGA treated animals, 
eosinophilia was significantly reduced compared to those given PBS alone (Figure 26).   
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Figure 25. Asthma model of IgE dependent, mast cell independent disease.  Mice 
were sensitized by OVA/Alum i.p. injection on days 0 and 14.  Aerosol challenge with 
1% OVA took place on days 19, 22, and  27.  On day 29 mice were sacrificed and BAL 
fluid was collected.  In these experiments, a liposome mixture was used to solubilize 
C70-TGA, thus a vehicle control, where mice are given liposome alone, is shown.  Mice 
were treated i.n. with C70-TGA or liposome throughout the experiment. 
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Figure 26. C70-TGA dampens eosinophilia in a model of IgE dependent, mast cell 
independent asthma.  Mice were treated as indicated in Figure 25.  Cells in the BAL 
fluid were stained with Hema 3 stain set.  Inflammatory cells in the BAL were counted 
and eosinophils are represented as a percentage of total inflammatory cells.  N = 4 mice 
per group.  ** = p<.01 using unpaired two tailed student t-test.   
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The vehicle control represents animals treated with liposomal medium because C70-
TGA was solubilized in this medium.  However, because eosinophilia is slightly reduced 
in the vehicle controls this medium was replaced with PBS for all other studies, and thus 
a vehicle control is unnecessary. 
 In addition to eosinophilia, cytokine levels were also assessed in the BAL fluid to 
determine the extent of C70-TGA inhibition.  Both IL-4 and IL-5 were significantly 
reduced following C70-TGA treatment (Figure 27).  This may explain, at least in part, the 
reduction in eosinophilia in this IgE dependent model.   
 A separate model of non-allergic lung inflammation that is independent of both 
mast cell function and IgE was utilized to examine both the efficacy and specificity of 
C70-TGA (Figure 28).  Individuals with non-allergic asthma generally have high levels of 
circulating IgE, but are non-responsive to skin prick tests 78.  It is generally thought that 
IgE in these individuals is not specific to allergen, although it is possible that an 
unidentified allergen is involved.  This model involves a period of strong stimulation with 
allergen which prompts the development of non-specific lung inflammation that is 
independent of typical immune mechanisms.  As we have found C70-TGA consistently 
inhibiting asthma pathogenesis in models that closely represent human disease and 
seen its ability to dampen mast cell and B cell function in vitro, we hypothesized it would 
have very little effect in this model of non-specific lung inflammation.   
 In this model of non-allergic lung inflammation shown in Figure 28, animals were 
sensitized with OVA in alum similar to the model described in Figure 25.  Lung 
challenge with OVA was much more severe, with seven daily challenges occurring from 
day 14 to day 20.  This caused the development of severe lung inflammation 
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Figure 27. C70-TGA reduces cytokine levels in a mast cell independent model of 
IgE dependent asthma.  Mice were treated as shown in Figure 25.  On day 29, BAL 
fluid was collected and cytokines were quantitated using a multiplex cytokine assay.  N 
= 4 mice per group.  * = p<.05 and ** = p<.01 using unpaired two tailed student t-test. 
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Figure 28. Non-allergic inflammatory model.  Mice were sensitized with OVA in alum 
on days 1 and 8.  Each day from day 14 to day 20, mice were challenged with 
aerosolized 1% OVA.  On day 21, mice were sacrificed and BAL fluid and lung tissues 
were collected. 
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independent of mast cells and IgE, as both mast cell deficient Wsh mice and IgE 
knockout mice develop inflammation similar to that seen in wild-type mice76.  Mice were 
sacrificed on day 21, and the bronchoalveolar lavage fluid was collected and analyzed 
for the presence of immune cells.  As expected, eosinophils were abundant in both C70-
TGA treated and PBS treated animals (Figure 29) and no significant difference was 
seen in cellular infiltration.  Cytokine levels in the BAL were also assessed, and again 
no difference was observed between C70-TGA and PBS treated animals (Figure 30).  
This data demonstrates the specificity of C70-TGA’s inhibitory effects on allergic 
responses. 
 Taken together, data presented in this section support the efficacy of C70-TGA for 
the treatment of asthma and allergic disease.  Next we attempt to define the mechanism 
by which C70-TGA functions in vivo. 
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Figure 29. C70-TGA has no effect on non-allergic lung inflammation.  Mice were 
treated as indicated in Figure 28.  Cells in the BAL fluid were stained with Hema 3 stain 
set.  Inflammatory cells in the BAL were counted and eosinophils are represented as a 
percentage of total inflammatory cells. N = 4-5 mice per group.  Results were not 
significant (NS) using an unpaired two-tailed student t-test.     
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Figure 30. C70-TGA does not inhibit BAL cytokines in a model of non-allergic lung 
inflammation.  Mice were treated as shown in Figure 28.  On day 21, BAL fluid was 
collected and cytokines were quantitated using a multiplex cytokine assay.  N = 4-5 
mice per group.  Results are not significant (NS) using an unpaired two-tailed student t-
test. 
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III. Proposed mechanism of C70-TGA action  
Asthma and allergic diseases are complex and involve the actions of several 
immune cells.  While we have shown that C70-TGA is capable of inhibiting mast cell and 
B cell function in vitro, it could have drastically different effects in vivo.  It is important to 
clarify the mechanism of action of this compound in order to prevent off-target and 
possibly toxic effects in the body.  Knowing the mechanism will also help define the 
usefulness of this compound for the treatment of asthmatic and other allergic diseases, 
and could assist in the identification of other disease targeting therapeutics in the future.  
The mechanism was assessed both by observing in vivo localization and by quantitating 
cellular mediators of disease in the serum and BAL fluid and relating this back to 
specific cell type involvement. 
To determine in vivo localization of fullerenes, a C70 compound was coupled to 
texas red (C70-TR) so that it could be visualized by immunohistochemistry.  Because 
C70-TGA has a profound effect on mast cells in vitro and on mast cell driven disease in 
vivo, we wanted to determine whether this compound is specifically localized to the 
mast cell in vivo or whether it has an indirect effect on mast cell function.  Naïve mice 
were given C70-TR intranasally and sacrificed 24 hours later.  Lungs were sectioned 
and stained with Anti-c-kit FITC in order to observe co-localization of mast cells (c-kit+) 
and the C70-TR compound.   Interestingly, in these naïve mice the compound appeared 
to specifically co-localize with c-kit+ mast cells in the lung (Figure 31).  While not all 
mast cells took up the C70-TR compound, it was only found localized within c-kit+ cells, 
and not in other unstained cells. 
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Figure 31. Fullerene C70-TR compound is found co-localized with c-kit+ mast 
cells in naïve mice.  Naïve mice were given 20 µg C70-Texas Red i.n. and sacrificed 
24 hours later.  Lungs were collected, sectioned, and stained with Anti-c-kit FITC.  
Overlay shows co-localization of C70-TR and c-kit+ mast cells.  
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Photos courtesy of Dr. Mohey El-Shikh 
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This co-localization was quite intriguing, but we wanted to be sure that the C70-
TR compound was also co-localized with mast cells in sensitized mice, when mast cells 
are recruited to the airways in large numbers.  Mice were sensitized and challenged as 
indicated in Figure 10, and animals were treated every three days with 20 µg C70-TR 
instead of C70-TGA.  Following OVA challenge mice were sacrificed and lungs were 
sectioned and stained with Anti-c-kit FITC.  Surprisingly, C70-TR was not taken up by 
mast cells which lined the airways in large quantities (Figure 32).  While there are a few 
mast cells that co-localize with the fullerene compound, the vast majority do not (Figure 
33).  In an attempt to explain this outcome, cells in the BAL fluid were quantitated and 
percentage eosinophils measured relative to other immune cells.  The percentage of 
eosinophils was not altered by C70-TR (data not shown), suggesting that its mechanism 
of action differs from that of C70-TGA.  Another possible explanation lies in the fact that 
macrophages weakly express c-kit, and thus the c-kit+ cells we see in figure 31 may 
actually be macrophages, not mast cells.  While C70-TGA may be interacting with mast 
cells in vivo, these studies could not support such a theory, most likely due to the 
structural differences between the two compounds.  
Immune mediators are produced by many cell types and play an important role in 
immunological diseases.  Cytokines are one form of immune mediator that function to 
initiate and maintain tissue inflammation.  Immune cells secrete many different 
cytokines that modulate immune responses.  Because allergic asthma is generally a 
Th2 response, we analyzed the BAL fluid for the presence of a panel of Th2 associated 
cytokines to determine if C70-TGA influences asthma pathogenesis by altering cytokine 
levels in the lung.  We found that after undergoing treatment as shown in the model in  
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Figure 32. In OVA sensitized mice C70-TR is not taken up by mast cells 
surrounding the airways.  Mice were sensitized and challenged as shown in Figure 7 
except C70-TR was given in place of C70-TGA.  Following OVA challenge mice were 
sacrificed and lungs were collected, sectioned, and stained with c-kit-FITC.  Overlay 
shows co-localization of C70-TR with c-kit+ mast cells. 
Photos courtesy of Dr. 
Mohey El-Shikh 
Fullerene C70 Texas Red Anti-c-kit FITC 
Overlay 
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Figure 33. The majority of mast cells do not take up C70-TR in OVA-sensitized 
mice.  Mice were sensitized and challenged as shown in Figure 10 except C70-TR was 
given in place of C70-TGA.  Following OVA challenge mice were sacrificed and lungs 
were collected, sectioned, and stained with c-kit-FITC.  Overlay shows co-localization of 
C70-TR with c-kit+ mast cells. 
Photos courtesy of Dr. 
Mohey El-Shikh 
Fullerene C70 Texas Red Anti-c-kit FITC 
Overlay 
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figure 10, both IL-5 and IL-4 levels were significantly reduced in C70-TGA treated 
animals compared to those treated with PBS (Figure 34).  This was consistent in all 
modelsstudied, particularly the established disease model (Figure 35), which is 
significant as this model best depicts therapeutic intervention in human disease.  This 
suggests that C70-TGA is altering more than just mast cell and B cell function in vivo as 
these cytokines are primarily produced by Th2 cells, and points to a multipotent 
inhibitory approach. 
Tetraglycolate reduced B cell IgE production in vitro, so we wanted to know how 
this inhibition translated in vivo.  Mice were pre-bled before initiation of each experiment 
in order to obtain baseline IgE levels and to ensure that the animals did not already 
have high IgE levels prompted by infection.  Animals were bled again two days before 
sacrifice and serum IgE levels were quantitated by ELISA.  In PBS treated animals, IgE 
was strongly induced following OVA challenge.  Tetraglycolate treated animals had 
some induction of IgE, but only about half as much was produced in PBS treated 
animals (Figure 36).  This may not have a dramatic effect on disease pathogenesis as 
IgE levels in C70-TGA treated mice are still greatly increased over non-sensitized 
animals, but it is clear that C70-TGA is capable of dampening B cell function to some 
degree in vivo. 
 Other mediators of interest are the eicosanoids, whose functions vary.  
Eicosanoids such as the leukotrienes and prostaglandins are known to have pro-
inflammatory activities that contribute to asthma pathogenesis.  Current therapeutics 
such as Singulair target the leukotrienes and have had mixed success treating 
asthmatic disease 79.  These and other eicosanoids can be quantitated by mass  
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Figure 34. C70-TGA treatment significantly reduces IL-4 and IL-5 levels in the BAL 
when given throughout sensitization and challenge.  Mice were treated as indicated 
in figure 10.  Bronchoalveolar lavage fluid was collected on day 47.  Cytokine levels in 
BAL fluid were measured using a multiplex cytokine assay.  N = 14 mice per group.  * = 
p<.05 using unpaired two tailed student t-test 
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Figure 35. C70-TGA treatment significantly reduces IL-5 and IL-4 levels in BAL 
fluid in an established model of asthma.  Mice were treated as indicated in figure 21.  
Bronchoalveolar lavage fluid was collected on day 76.  Cytokine levels in BAL fluid were 
measured using a multiplex cytokine assay.  N = 6 mice per group.  * = p<.05 using 
unpaired two tailed student t-test. 
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Figure 36. C70-TGA significantly reduced serum IgE levels in vivo.  Mice were 
treated as indicated in Figure 10.  Serum was collected following OVA i.n. challenge 
and assayed by ELISA for the presence of IgE.  N = 9 mice per group.  * = p<.05  using 
unpaired two tailed student t-test. 
 
 
 
 
 
 
 
 
  
73 
 
spectrometry, which we attempted to do in the BAL fluid.  Unfortunately we found that 
many prostaglandins and leukotrienes are too unstable to be measured in BAL fluid 
collected from our diseased mice, but were able to measure several of the more stable 
eicosanoids such as cis-epoxyeicosatreinoic acid (EET) and hydroxyeicosatetraenoic  
acid (HETE).  Interestingly, C70-TGA upregulates 11,12-EET, an anti-inflammatory 
eicosanoid consistently associated with relaxation of the bronchi and other anti-
inflammatory actions in vivo 63-65 (Figure 37).  Other eicosanoids were largely 
unaffected by C70-TGA (Table 1).   Experiments using purified human lung MC 
demonstrated that both 11,12 EET and 14,15 EET significantly stabilized MC 
challenged through FcεRI inhibiting both degranulation and cytokine production 
compared to non-EET treated cells (Figure 38). The 8,9 EET did not demonstrate any 
inhibition of MC mediator release (not shown). 
The EETs are produced by cytochrome P450 proteins, whose RNA expression 
can be measured and correlates with EET production.  Microarray was performed on 
human mast cells treated with or without C70-TGA in order to identify genes that are 
affected by C70-TGA.  A significant increase in RNA levels of the cytochrome P450 
protein CYP1B1 was seen in these cells (Figure 39), suggesting that this mechanism 
may be translatable to human disease. 
 In order to show a direct association between C70-TGA upregulation of EET’s and 
the improved asthma pathogenesis we see in C70-TGA treated mice, an EET inhibitor 
was employed.  This compound, 6-(2-Propargyloxyphenyl) hexanoic acid (PPOH), 
inhibits the formation of 11,12-EET by inhibiting epoxide formation by CYP4A2 and 
CYP4A380.  To examine the effect of EET inhibition on the severity of asthma  
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Figure 37. C70-TGA upregulates 11, 12 EET production in BAL fluid.  Mice were 
treated as shown in Figure 10.  Bronchoalveolar lavage fluid was collected following 
OVA i.n. challenge and assayed by mass spectrometry for the presence of EETs.  Fold 
change over non-sensitized animals is plotted.  N = 6 mice per group.  * = p<.05 using 
unpaired two tailed student t-test. 
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                                                                  Figure courtesy of Anthony Dellinger 
 
Figure 38.  Epoxygenases reduce degranulation and cytokine production from 
human lung mast cells after anti-FcRI activation.  Cells were cultured with fixed 
concentrations of the indicated EET or Vehicle Control (VC: Ethanol 40 µM), washed 
and stimulated for 20 min with optimal concentrations of anti-FcRI Abs (3B4; 1mg/ml). 
Cells were centrifuged and -hexosaminidase release and cytokine production 
determined. The data shown are the average of two separate experiments performed in 
triplicate with means ± SE shown. The asterisk indicated statistical significance 
compared to VC, where *= p<.05 using unpaired two tailed student t-test. 
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Table 1. C70-TGA has no effect on these eicosanoids.  Mass spectrometry was 
performed on BAL fluid from mice treated as indicated in Figure 10.  Eicosanoid levels 
were quantitated. 
 
 
 
 
Mean fold change (+/- SD) relative to non-sensitized 
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Figure 39. C70-TGA upregulates CYP1B1 expression in human mast cells.  Human 
skin mast cells were pre-treated with or without 10 µg/mL C70-TGA overnight at 37°.  
The next day cells were washed and challenged with or without anti- FcεRI  (1 µg/mL) 
for 2 hours.  Cell pellets were used for RNA isolation and gene microarray.  Relative 
gene expression of CYP1B1 is shown.  Each condition was performed in triplicate.  ** = 
p<.01 using unpaired two tailed student t-test. 
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pathogenesis, asthma was induced as indicated in Figure 10 and mice were treated 
with PBS, C70-TGA, or C70-TGA and PPOH.  Just as we hypothesized, the inhibition 
seen in C70-TGA treated animals is completely reversed in those given C70-TGA and 
PPOH.  Mice treated with PPOH and C70-TGA have significantly more eosinophils in the 
BAL fluid then those given C70-TGA alone.  Eosinophil levels in PPOH treated animals 
are similar to those seen in PBS treated animals, and are significantly greater than C70-
TGA treated and non-sensitized controls (Figure 40).  Bronchoconstriction  was also 
measured in these animals, and correlated with our findings on eosinophil infiltration.  
While C70-TGA inhibited bronchoconstriction as shown previously, PPOH completely 
reversed this inhibition (Figure 41).  Mice treated with PPOH had significantly higher 
airway constriction compared to C70-TGA treated animals, and values were similar to 
those seen in PBS treated mice.  When the mice were sacrificed, lungs were collected 
then sectioned and stained with H&E.  These sections show dramatic cellular infiltration 
in animals treated with PPOH and C70-TGA, similar to what is seen in PBS treated 
animals (Figure 42).  Conversely, mice treated with C70-TGA alone have minimal 
cellular infiltration and lung sections appear similar to non-sensitized mice. 
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Figure 40. PPOH reverses inhibition of eosinophilia in C70-TGA treated mice.  Mice 
were treated as indicated in Figure 10.  The EET inhibitor PPOH was given i.n. 15 
minutes prior to and again 2 hours following C70-TGA treatment.  Cells in the BAL fluid 
were stained with Hema 3 stain set.  Inflammatory cells in the BAL were counted and 
eosinophils are represented as a percentage of total inflammatory cells.  n=6 mice per 
group.  * = p<.05 and ** = p<.01 using unpaired two tailed student t-test. 
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Figure 41. PPOH reverses inhibitory effect of C70-TGA on bronchoconstriction.  
Mice were treated as indicated in Figure 10.  The EET inhibitor PPOH was given i.n. 15 
minute prior to and again 2 hours following C70-TGA treatment.  Maximum airway 
resistance in response to methacholine is plotted.  n = 6 mice per group.  * = p<.05 
using unpaired two tailed student t-test. 
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Figure 42. Lung sections show reversal of C70-TGA-induced inhibition of cellular 
infiltration by PPOH.  Lung tissue was fixed in 10% formalin, sectioned, and stained 
with H&E.  Bar measures 100 µm.  Representative photographs are shown. 
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IV. Toxic potential of C70-TGA 
 The C70-TGA compound was selected for study due to its specific inhibition of 
mast cell function, but its toxic potential remains unknown.  Because each derivatized 
fullerene compound contains a unique chemical formulation that determines the 
biological function of the molecule, toxicity must be determined separately.  The 
investigations discussed here are preliminary in nature, but suggest that C70-TGA has 
no overt toxic effects in vivo. 
A.  Effect of C70-TGA on liver and kidney function.  The toxicity of FD is still 
widely debated and varies based on the specific moieties added to the fullerene core 81.  
Therefore, in vivo toxicity of C70-TGA was assessed via several methods.  To assess 
liver function, serum levels of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were measured by ELISA using serum collected on the final 
treatment day using the model in Figure 10.  These enzymes are present at low levels 
in healthy individuals and large increases would suggest liver toxicity 82.  No significant 
differences were seen between treated, untreated, and non-sensitized control animals 
(Figure 43).  Additionally, serum creatinine levels were measured in order to assess 
kidney toxicity, as creatinine levels rise in the serum if the kidney is not properly filtering 
the blood 83.  No significant differences were seen between treated, untreated, and non-
sensitized animals (Figure 44).  This suggests that short-term use of C70-TGA is not 
toxic to major organs, although further testing is necessary to confirm this finding in 
human studies. 
B.  Levels of C70-TGA in major organs following i.n. treatment.  To assess 
toxic aggregation and build up in the body, a C70-TGA molecule containing gadolinium  
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Figure 43. C70-TGA has no effect on liver enzymes AST and ALT.  Serum was 
collected from C70-TGA treated mice on the final day of treatment (Figure 10).  Liver 
enzymes AST and  ALT were measured by ELISA.  N = 8 mice per group. Data is not 
significant (NS) using unpaired two-tailed student t-test. 
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Figure 44. C70-TGA has no effect on serum creatinine levels, a measure of kidney 
toxicity.  Serum was collected from C70-TGA treated mice on the final day of treatment 
(Figure 10).  Creatinine levels were measured by ELISA.  N = 6 mice per group.  Data is 
not significant using an unpaired two-tailed student t-test. 
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(Gd) within the fullerene sphere 84 was administered i.n. to mice every three days for 30 
days.  Twenty-four hours after the last dosage gadolinium levels were measured in 
serum, lung, spleen, liver, kidney, and brain tissue.  Gadolinium was detected only in 
the lung tissue, where less than 10 percent of that injected remained in the tissue.  No 
Gd was detected in any other tissue examined (data not shown).   
While further testing is necessary, these initial studies suggest that C70-TGA 
does not accumulate within the body and is not acutely toxic to the liver or kidney.   
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Discussion 
I.  Fullerene C70 Derivatives inhibit mast cell and B cell responses in vitro 
 Fullerenes are unique compounds whose therapeutic potential is only beginning 
to be studied.  These molecules are natural antioxidants with an ability to react with and 
neutralize reactive oxygen species (ROS), making them natural candidates for study in 
diseases caused by the overabundance of ROS. Their effectiveness as MRI contrast 
agents and inhibitors of neurodegenerative disease has been shown previously85, 
however very little research has been done to determine efficacy in other inflammatory 
diseases. 
 While fullerene derivatives may have the ability to dampen pathogenesis of 
several inflammatory disorders, our focus was on asthma and allergic diseases.  
Fullerene derivatives developed by Luna Innovations, Incorporated were tested for their 
ability to inhibit mast cells in vitro.  Because mast cells are important mediators of 
allergic disease, and C70-TGA is a potent inhibitor of mast cell degranulation and 
cytokine production, we hypothesized that this compound may be capable of reducing 
symptoms in mast cell driven disease.  In vitro studies revealed C70-TGA’s ability to 
reduce B cell IgE production, which focused our studies more intently on asthmatic 
disease.  There is a need for novel therapeutics to treat asthmatic disease as 
approximately fifty-five percent of patients with moderate to severe asthma have 
uncontrolled symptoms, despite receiving treatment 86.  While patients with mild to 
moderate asthma are able to control disease using non-specific anti-inflammatories 
such as inhaled corticosteroids, or in some cases by inhibiting mast cell mediators using 
anti-histamines or leukotriene inhibitors, these therapies are not always effective in 
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severe asthmatics 87.  Even when non-specific inhibitors such as the inhaled 
corticosteroids are effective, they can have other potentially toxic effects on the body 88.  
The data presented here show C70-TGA has specific immune targeting inhibitory effects 
as well as the ability to dampen both aspects of disease pathogenesis, airway 
inflammation and bronchoconstriction, something most asthma therapeutics are 
incapable of. 
One therapeutic capable of limiting both airway inflammation and 
bronchoconstriction is omalizumab (Xolair), which has been successful at controlling 
asthma by limiting MC and basophil activation 89.  This humanized IgE specific IgG1 
monoclonal antibody controls asthma by limiting the amount of free IgE available to bind 
FcεRI on the surface of MC and basophils.  These cells then reduce expression of the 
high affinity receptor limiting antigen crosslinking, activation and degranulation.  In 
patients with moderate to severe asthma omalizumab has been highly successful in 
controlling airway inflammation and reducing symptoms which can sometimes be 
severe enough to lead to hospitalization or even death.  While omalizumab has been 
successful due to its novel mechanism of action, its distribution is limited due to cost 
and method of administration (injection).  Another mast cell stabilizer, Cromolyn, has 
been effectively used to treat asthma and allergic rhinitis for many years.  Due to an 
inconvenient dosing regimen and lack of efficient drug delivery it is no longer widely 
used in the United States, although many other countries continue to use cromolyn 
because of its known efficacy and favorable safety record 90.  Tetraglycolate is intended 
to similarly stabilize mast cells thus reducing the presence and exacerbation of asthma 
symptoms.  Due to the remarkable stability of the fullerene carbon cage and our ability 
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to introduce these small molecules directly to sites of inflammation, C70-TGA may be an 
effective yet safe and easy to administer alternative to current therapeutics.   
In the development of C70-TGA, thought was given to both efficacy and safety.  
The compound was created using C70 as the core instead of C60 for two reasons. First, 
because C70 has ten more carbon atoms than C60, it is a slightly more effective free-
radical scavenger, which may improve its therapeutic benefit.  Secondly, the C70 
molecule tends to have an oval shape, and chemical moieties are more likely to react at 
the poles then throughout the molecule.  From the drug development point of view, this 
is an advantage because the number of isomers is reduced.  Historically, it has been 
seen that each chemical isomer can have a different and in some cases toxic effect, as 
was the case with thalidomide in the mid-1900’s 91.  Compounds using the C70 core may 
have an easier time gaining approval for clinical use, so even preliminary experiments 
such as these should be carried out using fullerene compounds that resemble a 
possible therapeutic option.   
 
II. C70-Tetraglycolate, a specifically derivatized fullerene compound, reduces 
pathogenesis of allergic asthma and anaphylaxis in vivo 
Anaphylaxis is a severe, life threatening reaction to allergen defined as the IgE 
mediated release of mast cell and basophil mediators following antigen crosslinking 92.  
It is not well anticipated, and thus prevention and treatment can be difficult 93.    At least 
1500 deaths each year are attributed to anaphylaxis, although it is likely that this 
number is an under-representation due to the lack of a proper diagnosis 92.  Because 
mast cells are a driving force in anaphylactic reactions, a model of passive systemic 
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anaphylaxis was utilized to quickly assess the efficacy of C70-TGA against mast cell 
driven disease in vivo.  Pathogenesis is due solely to mast cell activation in this model 
because IgE is injected, not produced by the animal’s own B cells.  As we hypothesized, 
C70-TGA was able to significantly reduce the drop in body temperature associated with 
anaphylaxis in part through the inhibition of the mast cell mediator histamine.  This 
prompted further investigation using models with active sensitization, where allergen is 
injected into the body and the immune system is allowed to react.  The majority of our 
studies focused on the interaction between C70-TGA and the immune system in this 
more natural model of immune sensitization. 
In order to properly characterize C70-TGA function, several models of asthma 
pathogenesis were utilized.   These models varied in their methods of allergen 
sensitization and challenge.  Models in which allergen is delivered in saline rather than 
in an adjuvant such as alum are thought to be more closely related to human disease as 
they rely heavily on the influence of mast cells.  Initially, C70-TGA was given i.n. 
throughout sensitization and challenge to determine in vivo efficacy in this mast cell 
influenced model.  Airway inflammation and bronchoconstriction were significantly 
reduced by C70-TGA compared to untreated animals.  In fact, total inflammation and 
bronchoconstriction in C70-TGA treated animals is not only significantly reduced, but is 
similar to that seen in non-sensitized controls.  Further, mice that were sensitized to 
OVA but untreated had a high mortality rate in response to methacholine.  Those that 
were given C70-TGA were much less susceptible to airway constriction and death upon 
exposure to methacholine.  Tetragolycolate treatment practically alleviated symptoms of 
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disease in these animals, and dramatically reduced allergen induced 
bronchoconstriction and death. 
While useful in evaluating the efficacy of this compound, these initial experiments 
do not address the issue that asthma is well established before therapeutic intervention 
begins.  For this reason, a model of established disease was developed in which C70-
TGA treatments begin only after asthma pathogenesis is induced.   The efficacy of C70-
TGA was then evaluated in this more clinically relevant model.  Consistent with the 
previous model in which mice were treated throughout disease development, we found 
C70-TGA dampens eosinophilia and cytokine levels significantly in the BAL fluid.  Lung 
sections show massive cellular infiltration in untreated animals, while those receiving 
C70-TGA have minimal cellular infiltration surrounding the airways.  Airway 
hyperresponsiveness was reduced in C70-TGA treated animals, although due to high 
variability between mice significant differences were not observed.  Thus, C70-TGA may 
be useful in a clinical setting to reverse asthma pathogenesis and limit exacerbation of 
symptoms.   
Other models of asthma pathogenesis in which sensitization was boosted by the 
use of the adjuvant alum were studied as well.  In these models, pathogenesis develops 
independent of mast cell function as the use of alum alters sensitization.  The first of 
these is an acute inflammatory model that, while shown to be mast cell independent, is 
dependent on IgE, as IgE KO animals do not develop eosinophilia76,77.  Pathogenesis is 
most likely mediated by basophils in this model.  Treatment with C70-TGA throughout 
allergen sensitization and challenge significantly reduced eosinophilia and cytokine 
levels in the BAL fluid, suggesting that C70-TGA is capable of inhibiting basophils in 
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addition to the effects on mast cell responses in vivo.  This is intriguing, as basophils 
are thought to play a role in human disease pathogenesis as these cells are recruited to 
the lungs in cases of fatal asthma 94. 
A similar model using alum to enhance sensitization was examined to determine 
the specificity of C70-TGA for allergic immune responses.  This model involved seven 
daily allergen challenges with aerosolized OVA, causing a severe non-allergic form of 
asthma pathogenesis.  In addition to being independent of mast cell function, 
pathogenesis developed independent of IgE as well, as IgE KO animals develop 
eosinophilia similar to wild-type76,77.  When given throughout allergen sensitization and 
challenge C70-TGA had no effect on eosinophilia or BAL cytokine levels in this model, 
suggesting that C70-TGA inhibits specific immune cells and allergic responses.   
 
III. Proposed mechanism of C70-TGA action  
In each of the models presented, inhibition of airway inflammation and 
bronchoconstriction corresponds with significant reductions in Th2 cytokines IL-4 and 
IL-5 in the BAL fluid.  This partially explains the mechanism of C70-TGA action.  
Interleukin-5 recruits and activates eosinophils, so it is not surprising that the significant 
reductions seen in eosinophil infiltration into the lung correspond with a significant 
reduction of this cytokine.  In response to IL-4 B cells undergo class switching to IgE, so 
inhibition of this cytokine may help explain the in vivo IgE reductions seen in C70-TGA 
treated animals.  However, in vitro B cell inhibition in the absence of T cells is also 
observed, and thus IL-4 inhibition alone may not fully explain the inhibitory effect of C70-
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TGA on B cell IgE production as this implies a more direct inhibition of B cell function by 
C70-TGA. 
The efficacy of omalizumab emphasizes the importance of IgE in allergic 
responses.  Inhibition of serum IgE levels in sensitized mice may be an important factor 
in the inhibitory mechanism of C70-TGA.    However, due to the high affinity of IgE for its 
receptor, FcεRI, relatively small amounts of IgE are needed to trigger degranulation in 
mast cells.  As an example, omalizumab, the only anti-IgE therapeutic currently 
available, reduces serum IgE levels by 84-99% 95 to induce efficacy.  Because serum 
IgE levels in C70-TGA treated animals are still greatly increased over non-sensitized 
mice, it is likely that IgE reduction only partially explains the inhibitory effects of C70-
TGA. 
Eicosanoids are generally thought to be pro-inflammatory molecules that play an 
important role in asthma pathogenesis.  These small molecules are derivatives of 
arachadonic acid, many of which are rapidly produced by activated mast cells.  There 
are three pathways commonly associated with eicosanoid production:  the lipoxygenase 
pathway, COX pathway, and cytochrome P450 pathway.  While derivatives of the COX 
and lipoxygenase pathways proved too unstable to measure in BAL fluid, several 
eicosanoids derived from the cytochrome P450 pathway are relatively stable and thus 
we measured these molecules in BAL fluid samples using mass spectrometry. 
Intriguingly, 11, 12 EET was consistently upregulated in BAL fluid from C70-TGA treated 
mice and was found capable of inhibiting degranulation and cytokine production by 
human mast cells in vitro.  The EETs are consistently associated with relaxation of the 
bronchi and other anti-inflammatory actions in vivo, 63-65  leading us to question the role 
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of these mediators in C70-TGA inhibition.  Further in vivo studies demonstrated that the 
EET’s play a major role in dampening the asthma phenotype as inhibitors of the EET’s 
prevented the C70-TGA-induced modulation of the OVA-induced asthma model.  We 
also find that C70-TGA upregulates expression of human lung mast cell CYP1B1, a gene 
involved in the production of EET’s that could be the source of 11, 12 EET. Lung 
epithelial and endothelial cells may also contribute as they are thought to be the main 
source of EET production 65,96. The EETs have been shown to relax histamine pre-
contracted guinea pig bronchi63  and can inhibit the upregulation of VCAM-1, E-selectin, 
and ICAM-1, thus potentially limiting cellular infiltration of the lung 65.  Consequently, 11, 
12 EET upregulation is playing a significant role in dampening airway inflammation and 
bronchoconstriction in these models. These results implicate the EET’s as a heretofore 
undiscovered mechanism for controlling asthma and suggest that strategies that induce 
the production of EET’s may be a viable therapeutic strategy for treating asthmatics.   
Originally we hypothesized that C70-TGA exerted its inhibitory effects primarily 
through mast cells.  But the data suggests that mast cells are just one of the many cell 
types inhibited by C70-TGA in vivo.  This may be of benefit as clinical disease is 
manifested differently in each individual patient, so the multipotent inhibition induced by 
C70-TGA may be capable of greater efficacy. 
The localization of C70-TGA in vivo is a big concern, as this affects both the 
toxicity and the inhibitory actions of the compound.  Several studies were carried out in 
an attempt to determine in vivo localization.  It is clear from the IR-800 studies that C70-
TGA is immediately present in the lung, but drains out completely sometime between 24 
hours and 4 days following i.n. instillation.  By giving C70-TGA i.n. every three days, we 
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hoped to maximize the inhibitory activity of the compound while reducing toxic build-up 
in the body.  But we were also interested in determining which cell types in the lung take 
up the compound, so we initiated the C70-TR studies.  Unfortunately C70-TGA itself 
cannot be bound to texas red as it quenches the dye, so a similarly derivatized C70 
molecule was used instead.  When the C70-TR compound was given to naïve mice 24 
hours prior to sacrifice, it appears the compound is localized within c-kit+ mast cells.  
However, when C70-TR is given in place of C70-TGA throughout allergen sensitization 
and challenge it is no longer found localized within mast cells, but appears to be taken 
up by macrophages instead.  This finding is probably explained by the fact that C70-TR 
does not inhibit airway inflammation and eosinophilia as C70-TGA does, so the two 
compounds are most likely using different mechanisms of action.  Most likely it is the 
size of the texas red dye molecule that alters the function of the C70-TR compound.  
Further studies attempting to show a direct interaction between mast cells and C70-TGA 
were unsuccessful as mast cells proved quite difficult to isolate from the lungs.  Given 
this, we can conclude that C70-TGA is localized to the lung for greater then 24 hours, 
and can inhibit B cell IgE production and inflammatory mediators released by T cells 
and mast cells.  But showing the direct interaction between these cells and C70-TGA has 
proved more challenging. 
 
IV. Toxic potential of C70-TGA 
Levels of liver enzymes AST and ALT, which are indicative of liver toxicity when 
present at high levels in the serum, were not different between treated and untreated 
animals. Tetraglycolate treated animals had creatinine levels 97 similar to those seen in 
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untreated animals, and all were within the normal range.  Thus, liver and kidney function 
appear to be unaffected by short-term local administration of C70-TGA.  In addition, a 
C70-TGA-like compound containing Gd within the fullerene core was developed so that 
its presence in tissue could be detected using ICP neutron bombardment. After one 
month of intranasal inhalations, only lung tissue contained detectable amounts of Gd.  
Thus C70-TGA does not appear to build up in the body tissues, limiting the possibility of 
toxicity.  Further testing will be necessary to determine the safety of these compounds 
in humans. 
 
V.  Conclusions and Significance 
 The goal of this research was to determine the efficacy of a specifically 
derivatized fullerene, C70-TGA, for the treatment of asthmatic disease and to provide its 
mechanism of inhibition.  Murine asthma models provide convincing evidence that C70-
TGA significantly reduces asthma pathogenesis to levels similar to that seen in non-
sensitized controls, which were never exposed to allergen.  Further, C70-TGA inhibited 
both aspects of disease, airway inflammation and bronchoconstriction, which most 
therapeutics are incapable of.  This was achieved through the inhibition of multiple 
immune cells.  In response to C70-TGA, mast cell degranulation was reduced, B cells 
produced less IgE, T cell cytokine production was inhibited, and the production of anti-
inflammatory mediators was induced in lung epithelial and endothelial cells.  The 
combination of these actions led to the in vivo inhibition of pathogenesis we observed.  
Further, no toxicity was observed in mice which supports the use of fullerene derivatives 
as pharmacological agents in the treatment of inflammatory diseases. 
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 These studies also uncovered a novel mechanism of asthma inhibition through 
the actions of 11, 12 EET.  While previous work found 11, 12 EET capable of inhibiting 
human bronchi and adhesion molecules in vivo, its function in vivo had not been 
explored.  This research represents the first time a role has been shown for the EET’s in 
controlling asthma, which could help to guide future research into the development of 
more targeted asthma therapeutics. 
  Derivatized fullerene compounds reduce airway inflammation and 
hyperresponsiveness in murine models of asthmatic disease, and we propose that once 
adequate modifications have been performed these molecules will have a role in the 
treatment of human asthmatic disease.  As specific manipulations to the fullerene core 
can direct the actions of these compounds, derivatized fullerenes may represent a 
targeted, non-toxic alternative to the corticosteroids.  While currently the most 
commonly used therapeutic for the treatment of asthma, inhaled corticosteroids are 
non-specific anti-inflammatory compounds and can be toxic at high doses 98.  Further, 
inhaled corticosteroids are not effective for the treatment of severe asthma.  While only 
10 percent of asthmatics suffer from severe asthma, this population acquires over 50 
percent of the total costs associated with disease 99,100. Thus, there is a need for 
alternative therapies.  This data suggests that derivatized fullerenes may provide dual 
functions, inhibiting both short term mediator release by immune cells as well as long 
term cytokine release and underlying inflammation.  Hence these unique compounds 
could potentially have greater efficacy than current treatments. 
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